Home  »  Business   »  Pfizer Inc. (NYSE: PFE) Has Yet To Impress Analyst...

Pfizer Inc. (NYSE: PFE) Has Yet To Impress Analysts?

Pfizer Inc. (NYSE:PFE) traded at $44.21 at last check on Tuesday, January 24, made a downward move of -1.71% on its previous day’s price.

Looking at the stock we see that its previous close was $44.98 and the beta (5Y monthly) reads 0.64 with the day’s price range being $44.82 – $45.32. The company has a trailing 12-month PE ratio of 8.53. In terms of its 52-week price range, PFE has a high of $56.32 and a low of $41.44. The company’s stock has lost about -12.35% over that past 30 days.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Pfizer Inc. has a market cap of $251.65 billion and is expected to release its quarterly earnings report on Feb 06, 2023 – Feb 10, 2023. With its Forward Dividend at 1.64 and a yield of 3.65%, the company’s investors could be anxious for the PFE stock to gain ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $15.52, with the EPS growth for the year raised at $69.21 for 2022 and $55.56 for next year. These figures represent 64.60% and -19.70% growth in EPS for the two years respectively.

Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $229.15 billion, with a low of $215.76 billion and a high of $238.32 billion. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $1.07T, or 38.60% up from figures reported last year.

There have been 1 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the PFE stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 22 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 12 have rated the Pfizer Inc. (PFE) stock as a Hold, while 10 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is -9.32% off its SMA20 and -10.83% from its 50-day simple moving average. The RSI (14) is pointing at 25.85 while the volatility over the past week is 1.66% and jumps to 1.92% over the past one month. The beta value is 0.66, while the average true range (ATR) is currently pointing at 1.10. The average price target for the stock over the next 12 months is $55.00, with the estimates having a low of $44.00 and a high of $75.00. These price ends are 0.48% and -69.64% off the today’s price level respectively, although investors could be excited at the prospect of a -19.88% if the PFE share price touches on the median price of $53.00.

Let’s briefly compare Pfizer Inc. (PFE) stock to its peers. We find that today’s price change of -1.71% and -16.78% over the past 12 months for PFE competes that of Johnson & Johnson (JNJ), which has seen its stock price fall -0.98% in the latest trading session and is 1.85% over the last one year. Another of its peers Eli Lilly and Company (LLY) has dropped -0.11% today, and was 40.75% up over the past year, while Abbott Laboratories (ABT) is also down -1.08% yet, while its price remains in the red at -8.58% over the same period. Pfizer Inc. has a P/E ratio of 8.53 compared to Johnson & Johnson’s 23.43 and Eli Lilly and Company’s 51.43. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -0.40% and -0.23%, respectively, in early deals.

Coming back to Pfizer Inc. (NYSE:PFE), we note that the average 3-month trading volume was 21.56 million, while that of the preceding 10-day period stands at 25.95 million. Current shares outstanding are 5.61 billion.

The insiders hold 0.05% of the company’s shares while institutions hold 70.50%. The data shows that short shares as of Oct 13, 2022, stood at 62.51 million at a short ratio of 3.19. This represents a 1.11% short interest in shares outstanding on Oct 13, 2022. Shares short fall in October from the previous month at 63.89 million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -12.22% down in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *

5 Lithium Stocks with High Future Potential

Demand for lithium is expected to increase 8-fold by 2030. The world's largest automakers are racing to go green as the global EV boom continues.

 

We have collated a list of top five lithium stocks which are well positioned to benefit from the 2023 lithium boom because of their focus on multiple high-potential lithium projects.

100% free. stop anytime no spam